AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma (CTMS# 23-0054)

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Anne–Marie Langevin MD

For more information about this study

View Details